| Revenue Growth | Plasma 18%, Med Surge 6%, Blood Management 7%, Interventional Technologies 3%. |
|---|---|
| Mgmt Confidence | High confidence in long-term high-20s operating margins despite near-term guidance cut. |
| Demand Visibility | Strong underlying plasma collections; CSL rollout confirmed through Q3 FY27. |
| Margin Trends | Operating margin guidance lowered to 0-50bps expansion from 50-100bps previously. |
| Op. Leverage | Expect significant leverage in FY28 as transitory CSL ramp-up costs subside. |
| Pricing Power | Persona Plus improves customer economics by increasing plasma yield and productivity. |
| Vol vs Price | Growth driven by share gains, Persona Plus adoption, and volume utilization. |
| Segment Growth | Plasma grew 18%; Transfusion Management grew double digits; Interventional Tech stabilized. |
| New Clients | Expanded CSL relationship; full Nexus PCS rollout to all US centers. |
| Capex & Debt | Repaid $100M debt year-to-date; net leverage at 2.5x EBITDA. |
| Regulatory | Received FDA approval for Vascade Elite; CE Mark for Vascade MVP XL. |
| Commentary | Focusing on turning durable revenue growth into lasting shareholder value. |
| New Launches | Launched Pace Pro Guide Wire and Vascade Elite for large bore. |
Growth
Organic revenue grew 10% in Q2; Plasma segment led with 18% growth.
Outlook
Raised FY27 organic revenue guidance to 6-9% and EPS growth to 8-11%.
Risks
Management lowered operating margin guidance due to transitory CSL ramp-up costs and inflationary pressures.
The company's earnings call, NYSE: HAE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Haemonetics Corp: key numbers
- Share price
- $121.34Close, Nov 16
- Market cap
- $5.53B
- Shares outstanding
- 45.54MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Haemonetics Corp
All →Haemonetics VP, CAO Farris Maryanne Maunsell Sells $101K of Stock
Farris Maryanne Maunsell, VP, CAO, sold 836 shares of Haemonetics Corp at $120.99 a share, worth $101K in total on Nov 11, 2026. Shares held after the trade: 5,828 (-12.5%).
- Value
- $101K
- Shares
- 836
- Price
- $120.99
- Role
- VP, CAO
- Holding change
- -12.5%
- Trade date
- Nov 11, 2026
Haemonetics Q2 2026 Results: Net Income $46.3M, Up 19.7% YoY
Haemonetics Corp reported net revenues of $357.8 million for the quarter ended September 26, 2026, a 9.3% increase compared to the prior year. Net income rose to $46.3 million, driven by higher gross profits and the absence of intangible asset impairments that occurred in the previous year's quarter.
- Key figure
- Net income $46.3M · +19.7% YoY
Haemonetics Financial Results
Haemonetics reported second quarter fiscal 2027 revenue of $358 million, a 9% increase driven by strong performance in its Apheresis business. The company achieved GAAP diluted EPS of $1.00 and adjusted diluted EPS of $1.35, benefiting from gross margin expansion and the transformation of its product portfolio toward higher-margin offerings.
- Term
- Q2 2027
“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”
Chris Simon, Haemonetics’ CEO
Haemonetics Business Update
Haemonetics provided a status update on its non-exclusive supply agreement with CSL Plasma, noting that CSL expects to complete the rollout of NexSys PCS devices and Persona PLUS disposables across all its U.S. collection centers by the end of 2027. The company maintained its existing fiscal 2027 guidance and plans to provide a detailed financial impact update during its November 2026 earnings call.
- Counterparty
- CSL Plasma Inc.
- Term
- through end of calendar year 2027